Inhaled Drugs for COPD Exacerbations
Author Information
Author(s): Milo A Puhan, Lucas M Bachmann, Jos Kleijnen, Gerben ter Riet, Alphons G Kessels
Primary Institution: Horten Centre for Patient Oriented Research and Knowledge Transfer, University of Zurich, Switzerland
Hypothesis
What is the relative effectiveness of different inhaled drug regimens in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD)?
Conclusion
No single inhaled drug regimen is more effective than another in reducing exacerbations in COPD patients.
Supporting Evidence
- All inhaled drug regimens significantly reduced exacerbations compared to placebo.
- Long-acting anticholinergics and inhaled corticosteroids were effective in patients with FEV1 ≤ 40%.
- Combination treatment did not show significant improvement over long-acting beta-agonists alone.
Takeaway
Doctors looked at different inhalers to see which one helps people with breathing problems the most, and they found that they all work about the same.
Methodology
A systematic review and network meta-analysis of randomized trials lasting at least 4 weeks.
Limitations
The analysis focused only on exacerbations and lacked individual patient FEV1 data.
Participant Demographics
The study included 26,786 patients with COPD, median age 64 years, 27% had at least one exacerbation.
Statistical Information
P-Value
0.02 for interaction
Confidence Interval
0.64 to 0.80 for long-acting anticholinergics; 0.70 to 0.86 for inhaled corticosteroids
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website